Climb Bio (CLYM) Gains from Investment Securities (2020 - 2025)

Climb Bio has reported Gains from Investment Securities for 6 years, with the latest figure at $1.3 million in Q4 2025.

• For the quarter ending Q4 2025, Gains from Investment Securities fell 79.77% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $7.7 million (up 3328.0% YoY), and the FY2025 full-year result was $6.4 million, up 128.12% from the prior year.
• Gains from Investment Securities for Q4 2025 stood at $1.3 million, down from $1.4 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $6.4 million in Q4 2024, with the low at $50000.0 in Q3 2023.
• Historically, Gains from Investment Securities has averaged $2.1 million across 5 years, with a median of $1.4 million in 2025.
• Annual changes were most pronounced in 2023 — Gains from Investment Securities plunged 98.9% — and 2024, when it jumped 3528.1%.
• Climb Bio's Gains from Investment Securities stood at $2.4 million in 2021, then soared by 89.92% to $4.5 million in 2022, then sank by 98.9% to $50000.0 in 2023, then soared by 12730.0% to $6.4 million in 2024, then sank by 79.77% to $1.3 million in 2025.
• The last three Gains from Investment Securities figures came in at $1.3 million (Q4 2025), $1.4 million (Q2 2025), and $225000.0 (Q1 2025), per Business Quant data.